Witness Name: Judith Paget

Statement No.: WITN5712011

Exhibits: WITN5712010

Dated: 20 February 2024

**INFECTED BLOOD INQUIRY**

---

**WRITTEN STATEMENT OF JUDITH PAGET**

---

I provide this statement in response to a request under Rule 9(1) and (2) of the Inquiry Rules 2006 dated 8 February 2024.

I, Judith Paget, will say as follows: -

**Access to recombinant blood products for children with Von Willebrand Disease (VWD)**

1. In November 2022, the One Wales Medicines Assessment Group (OWMAG) recommended that vonicog alfa (Veyvondi) should be made available within NHS Wales for on-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with von Willebrand disease [**WITN5712010**]. The OWMAG recommended the advice should be reviewed within 12 months or sooner should new evidence arise.

2. In the absence of new evidence, the OWMAG's recommendation was reviewed in December 2023 and endorsed by the All Wales Medicines Strategy Group. The recommendation was subsequently ratified by Welsh Ministers. All our health boards are expected to comply with the recommendation.

3. The recommendation states vonicog alfa can be made available for off-label prescribing within NHS Wales for on-demand treatment of non-surgical and surgical (elective and emergency) bleeding episodes in children aged up to 17 years with von Willebrand disease using the agreed starting and stopping criteria described in the OWMAG recommendation.

4. I am not aware that vonicog alfa is routinely available in the other UK nations for the treatment of von Willebrand disease in people under 18 years.

**Statement of Truth**

I believe that the facts stated in this witness statement are true.

Signed GRO-C

Dated 20 February 2024

**Table of exhibits:**

| Date | Notes/ Description | Exhibit number |
|---|---|---|
| December 2023 | OWMAG recommendation: vonicog alfa | WITN5712010 |
| | | |